Trial Outcomes & Findings for Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy (NCT NCT04810546)
NCT ID: NCT04810546
Last Updated: 2026-02-17
Results Overview
% of women approach and eligble who enrolled
COMPLETED
NA
23 participants
Recruitment duration- approximately 3 years
2026-02-17
Participant Flow
Participant milestones
| Measure |
Jarrow Formulas Oral Bovine Lactoferrin Supplement
Once daily Oral Lf (250mg). Women assigned to this group will be instructed to consume an oral Lf capsule one hour prior to their afternoon meal and two prenatal vitamin/mineral supplement gummies without iron with omega-3 fatty acids before bed from early second trimester (15 - 20 WG) up through delivery. Women are advised to consume the Lf prior to meals, given our team member Valenti's unpublished work shows its superior efficacy for improving iron and hematological parameters among pregnant women with hereditary thrombophilia versus when consumed with meals. The prenatal vitamin/mineral gummies will be a commercially available product (One-a-Day Women's Prenatal Gummies with omega-3 fatty acids, Bayer Healthcare, Whippany, NJ). Women in both groups will be advised to consume an iron-rich diet and provided a handout detailing foods rich in heme and non-heme iron.
Jarrow Formulas Oral Bovine Lactoferrin Supplement: Lactoferrin (Apolactoferrin) 250mg contains \~17.6 mg/100g of iron
|
Usual Care
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
|---|---|---|
|
Overall Study
STARTED
|
12
|
11
|
|
Overall Study
COMPLETED
|
7
|
7
|
|
Overall Study
NOT COMPLETED
|
5
|
4
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy
Baseline characteristics by cohort
| Measure |
Jarrow Formulas Oral Bovine Lactoferrin Supplement
n=12 Participants
Once daily Oral Lf (250mg). Women assigned to this group will be instructed to consume an oral Lf capsule one hour prior to their afternoon meal and two prenatal vitamin/mineral supplement gummies without iron with omega-3 fatty acids before bed from early second trimester (15 - 20 WG) up through delivery. Women are advised to consume the Lf prior to meals, given our team member Valenti's unpublished work shows its superior efficacy for improving iron and hematological parameters among pregnant women with hereditary thrombophilia versus when consumed with meals. The prenatal vitamin/mineral gummies will be a commercially available product (One-a-Day Women's Prenatal Gummies with omega-3 fatty acids, Bayer Healthcare, Whippany, NJ). Women in both groups will be advised to consume an iron-rich diet and provided a handout detailing foods rich in heme and non-heme iron.
Jarrow Formulas Oral Bovine Lactoferrin Supplement: Lactoferrin (Apolactoferrin) 250mg contains \~17.6 mg/100g of iron
|
Usual Care
n=11 Participants
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
Total
n=23 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
5 Participants
n=25 Participants
|
8 Participants
n=20 Participants
|
13 Participants
n=45 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=25 Participants
|
0 Participants
n=20 Participants
|
1 Participants
n=45 Participants
|
|
Age, Continuous
|
28.1 years
STANDARD_DEVIATION 5.45 • n=25 Participants
|
27.1 years
STANDARD_DEVIATION 5.12 • n=20 Participants
|
27.6 years
STANDARD_DEVIATION 5.19 • n=45 Participants
|
|
Sex: Female, Male
Female
|
12 Participants
n=25 Participants
|
11 Participants
n=20 Participants
|
23 Participants
n=45 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=25 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=45 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
6 Participants
n=25 Participants
|
3 Participants
n=20 Participants
|
9 Participants
n=45 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
2 Participants
n=25 Participants
|
0 Participants
n=20 Participants
|
2 Participants
n=45 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=25 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=45 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=25 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=45 Participants
|
|
Race (NIH/OMB)
Black or African American
|
5 Participants
n=25 Participants
|
8 Participants
n=20 Participants
|
13 Participants
n=45 Participants
|
|
Race (NIH/OMB)
White
|
4 Participants
n=25 Participants
|
2 Participants
n=20 Participants
|
6 Participants
n=45 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=25 Participants
|
1 Participants
n=20 Participants
|
1 Participants
n=45 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=25 Participants
|
0 Participants
n=20 Participants
|
1 Participants
n=45 Participants
|
|
Region of Enrollment
United States
|
12 Participants
n=25 Participants
|
11 Participants
n=20 Participants
|
23 Participants
n=45 Participants
|
|
Screening Hemoglobin g/dL12
|
12.18 grams per deciliter
STANDARD_DEVIATION 0.58 • n=25 Participants
|
12.2 grams per deciliter
STANDARD_DEVIATION 0.44 • n=20 Participants
|
12.19 grams per deciliter
STANDARD_DEVIATION 0.51 • n=45 Participants
|
PRIMARY outcome
Timeframe: Recruitment duration- approximately 3 yearsPopulation: Number of women eligible and approached.
% of women approach and eligble who enrolled
Outcome measures
| Measure |
Overall Goal Was > 30% of Women Eligible Who Were Approached
n=230 Participants
overall recruitment rate for the study with a goal of recruiting \>= 30% of those approached who were eligible
|
Usual Care
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
|---|---|---|
|
Recruitment Feasibility
|
10 percentage eligible and enrolled
|
—
|
PRIMARY outcome
Timeframe: 8 monthsHand pill counts by the investigational drug service to determine % days compliant while enrolled in the trial
Outcome measures
| Measure |
Overall Goal Was > 30% of Women Eligible Who Were Approached
n=11 Participants
overall recruitment rate for the study with a goal of recruiting \>= 30% of those approached who were eligible
|
Usual Care
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
|---|---|---|
|
Participant Adherence to Lactoferrin - Interventiom Arm
|
82.1 percentage of days adherent
Standard Deviation 12.9
|
—
|
PRIMARY outcome
Timeframe: 8 months% of women retained by study arm through the end of the study (labor and delivery)
Outcome measures
| Measure |
Overall Goal Was > 30% of Women Eligible Who Were Approached
n=12 Participants
overall recruitment rate for the study with a goal of recruiting \>= 30% of those approached who were eligible
|
Usual Care
n=11 Participants
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
|---|---|---|
|
Participant Retention
|
58 percentage of participants retained
|
63 percentage of participants retained
|
SECONDARY outcome
Timeframe: interval of 5-6 months% change in C-reactive protein from baseline to third trimester measured in serum at baseline and in the third trimester of pregnancy
Outcome measures
| Measure |
Overall Goal Was > 30% of Women Eligible Who Were Approached
n=10 Participants
overall recruitment rate for the study with a goal of recruiting \>= 30% of those approached who were eligible
|
Usual Care
n=7 Participants
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
|---|---|---|
|
% Change in C-reactive Protein mg/L Between Baseline and Third Trimester
|
-10.4 percentage of change from baseline
Standard Deviation 44.5
|
26.6 percentage of change from baseline
Standard Deviation 91.9
|
SECONDARY outcome
Timeframe: Following delivery of the neonatemeasured from cord blood obtained following labor and delivery
Outcome measures
| Measure |
Overall Goal Was > 30% of Women Eligible Who Were Approached
n=6 Participants
overall recruitment rate for the study with a goal of recruiting \>= 30% of those approached who were eligible
|
Usual Care
n=5 Participants
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
|---|---|---|
|
Cord Ferritin ng/mL
|
177.67 ng/mL
Standard Deviation 190.46
|
133.40 ng/mL
Standard Deviation 98.85
|
SECONDARY outcome
Timeframe: Following delivery of the neonateCord CBC. Cord CBC which includes Hb, will at following labor and delivery
Outcome measures
| Measure |
Overall Goal Was > 30% of Women Eligible Who Were Approached
n=6 Participants
overall recruitment rate for the study with a goal of recruiting \>= 30% of those approached who were eligible
|
Usual Care
n=4 Participants
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
|---|---|---|
|
Cord Hemoglobin g/dl
|
14.93 g/dL
Standard Deviation 0.77
|
14.05 g/dL
Standard Deviation 1.32
|
SECONDARY outcome
Timeframe: interval of 5-6 months% change in maternal ferritin measured from serum obtained at baseline and the third trimester of pregnancy
Outcome measures
| Measure |
Overall Goal Was > 30% of Women Eligible Who Were Approached
n=10 Participants
overall recruitment rate for the study with a goal of recruiting \>= 30% of those approached who were eligible
|
Usual Care
n=7 Participants
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
|---|---|---|
|
% Change in Maternal Ferritin ng/mL
|
-17.4 percentage of change from baseline
Standard Deviation 135.8
|
-75.0 percentage of change from baseline
Standard Deviation 12.0
|
SECONDARY outcome
Timeframe: interval of 5-6 monthsmeasured from whole blood at baseline and in the third trimester of pregnancy
Outcome measures
| Measure |
Overall Goal Was > 30% of Women Eligible Who Were Approached
n=10 Participants
overall recruitment rate for the study with a goal of recruiting \>= 30% of those approached who were eligible
|
Usual Care
n=7 Participants
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
|---|---|---|
|
% Change in Maternal Hemoglobin mg/dl
|
8.0 percentage of change from baseline
Standard Deviation 8.6
|
6.1 percentage of change from baseline
Standard Deviation 8.3
|
Adverse Events
Jarrow Formulas Oral Bovine Lactoferrin Supplement
Usual Care
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Jarrow Formulas Oral Bovine Lactoferrin Supplement
n=12 participants at risk
Once daily Oral Lf (250mg). Women assigned to this group will be instructed to consume an oral Lf capsule one hour prior to their afternoon meal and two prenatal vitamin/mineral supplement gummies without iron with omega-3 fatty acids before bed from early second trimester (15 - 20 WG) up through delivery. Women are advised to consume the Lf prior to meals, given our team member Valenti's unpublished work shows its superior efficacy for improving iron and hematological parameters among pregnant women with hereditary thrombophilia versus when consumed with meals. The prenatal vitamin/mineral gummies will be a commercially available product (One-a-Day Women's Prenatal Gummies with omega-3 fatty acids, Bayer Healthcare, Whippany, NJ). Women in both groups will be advised to consume an iron-rich diet and provided a handout detailing foods rich in heme and non-heme iron.
Jarrow Formulas Oral Bovine Lactoferrin Supplement: Lactoferrin (Apolactoferrin) 250mg contains \~17.6 mg/100g of iron
|
Usual Care
n=11 participants at risk
Women assigned to this group will be instructed to consume a commercially available prenatal vitamin/mineral supplement with iron and omega-3 fatty acids (Prenatal 1, Bayer Healthcare, Whippany, NJ) before bed from early second trimester (15-20 WG) through delivery. To minimize variability in prenatal vitamin/supplement use across the participants, we have opted to standardize the prenatal vitamin/mineral supplement by providing women in the usual care arm a supplement that is nutritionally like what is prescribed by the Center for Women's Health providers. Women will be advised to consume an iron-rich diet and provided a handout describing foods rich in heme and non-heme iron.
|
|---|---|---|
|
Gastrointestinal disorders
Non-serious AE
|
58.3%
7/12 • Number of events 24 • 8 months
|
36.4%
4/11 • Number of events 4 • 8 months
|
|
Pregnancy, puerperium and perinatal conditions
Obstetrics ER visit non-Gastrointestinal
|
33.3%
4/12 • Number of events 4 • 8 months
|
36.4%
4/11 • Number of events 4 • 8 months
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place